Page last updated: 2024-11-06

elmustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

elmustine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68804
CHEMBL ID284907
SCHEMBL ID93476
MeSH IDM0061997

Synonyms (31)

Synonym
elmustine
nsc294895
wln: q2mvnno&2g
hecnu
urea, 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitroso-
1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea
urea, n-(2-chloroethyl)-n'-(2-hydroxyethyl)-n-nitroso-
nsc-294895
60784-46-5
hydroxyethyl cnu
n-(2-chloroethyl)-n'-(2-hydroxyethyl)-n-nitrosourea
ccris 3034
einecs 262-429-1
elmustina [spanish]
elmustinum [latin]
n-hydroxyethyl-n-chloroethyl-nitrosourea
elmustine [inn]
1-nitroso-1-chloroethyl-3-hydroxyethylurea
brn 1956525
cnu-ethanol
1-(2-hydroxyethyl)-3-(2-chloroethyl)-3-nitrosourea
CHEMBL284907
AKOS006274246
elmustinum
elmustina
unii-nat2fd82d7
nat2fd82d7 ,
elmustine [mart.]
SCHEMBL93476
DTXSID80209610
Q27284767

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Pretreatment with DSF (1000 mg/kg) resulted in identical or slightly higher life expectancies; it thus reduced the toxic side effects of HECNU without inhibiting its antitumor potency."( Effect of the pretreatment with disulfiram on the toxicity and antitumor activity of 1-(2-hydroxyethyl)-3-(2-chloroethyl)-3-nitrosourea in Sprague--Dawley rats.
Habs, H; Habs, M, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID116939Median survival time including day-60 survivors (MST), after post implantation at the optimal dose of 6.25 mg/kg; d=Not attained1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Studies on synthesis and anticancer activity of selected N-(2-fluoroethyl)-N-nitrosoureas.
AID116429Optimal percentage of increased life span [(100 x MST treated mice / MST control mice) -100] at the optimal dose of 6.25 mg/kg; d=Not Attained1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Studies on synthesis and anticancer activity of selected N-(2-fluoroethyl)-N-nitrosoureas.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID120330Number of day-60 survivors at the optimal dose of 6.25 mg/kg; 9/101984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Studies on synthesis and anticancer activity of selected N-(2-fluoroethyl)-N-nitrosoureas.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (61.11)18.7374
1990's13 (36.11)18.2507
2000's1 (2.78)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.31 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.05 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.13%)5.53%
Reviews2 (5.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (89.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]